Terms: = Liver cancer AND WHSC1, 7468, O96028, WHS, TRX5, REIIBP, NSD2, MMSET, MGC176638, KIAA1090, FLJ23286
13 results:
1. Novel dual-targeting inhibitors of nsd2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and
Jin X; Wang Y; Chen J; Niu M; Yang Y; Zhang Q; Bao G
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2289355. PubMed ID: 38059332
[TBL] [Abstract] [Full Text] [Related]
2. whsc1 is involved in DNA damage, cellular senescence and immune response in hepatocellular carcinoma progression.
Yan J; Zhang MY; Lin J; Li KX; Zhao ZM; Gao YM; Deng XL; Wang CS; Wang HS
J Cell Mol Med; 2023 May; 27(10):1436-1441. PubMed ID: 37073435
[TBL] [Abstract] [Full Text] [Related]
3. Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the whsc1-mediated TOP2A/PI3K/AKT axis.
Bao ZM; Yao D; Qian X; Zhang HG; Yang M; Guo YH; Qin L
Kaohsiung J Med Sci; 2022 Jul; 38(7):662-674. PubMed ID: 35394699
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive Bioinformatics Analysis of Key Methyltransferases and Demethylases for Histone Lysines in Hepatocellular Carcinoma.
Zheng Y; Tang L; Chen G; Liu Z
Technol Cancer Res Treat; 2020; 19():1533033820983284. PubMed ID: 33355042
[TBL] [Abstract] [Full Text] [Related]
5. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic cancer Patients Receiving Neoadjuvant Treatment.
Yoon KA; Woo SM; Kim YH; Kong SY; Lee MK; Han SS; Kim TH; Lee WJ; Park SJ
Gut Liver; 2019 Nov; 13(6):683-689. PubMed ID: 30970447
[TBL] [Abstract] [Full Text] [Related]
7. nsd2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling.
Chen LY; Zhi Z; Wang L; Zhao YY; Deng M; Liu YH; Qin Y; Tian MM; Liu Y; Shen T; Sun LN; Li JM
J Pathol; 2019 May; 248(1):103-115. PubMed ID: 30666650
[TBL] [Abstract] [Full Text] [Related]
8. Discovery platform for inhibitors of IgH gene enhancer activity.
Dolloff NG
Cancer Biol Ther; 2019; 20(4):571-581. PubMed ID: 30481117
[TBL] [Abstract] [Full Text] [Related]
9. Risk of hepatic neoplasms in Wolf-Hirschhorn syndrome (4p-): Four new cases and review of the literature.
Battaglia A; Calhoun ARUL; Lortz A; Carey JC
Am J Med Genet A; 2018 Nov; 176(11):2389-2394. PubMed ID: 30289612
[TBL] [Abstract] [Full Text] [Related]
10. Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis.
Kuramoto J; Arai E; Tian Y; Funahashi N; Hiramoto M; Nammo T; Nozaki Y; Takahashi Y; Ito N; Shibuya A; Ojima H; Sukeda A; Seki Y; Kasama K; Yasuda K; Kanai Y
Carcinogenesis; 2017 Mar; 38(3):261-270. PubMed ID: 28426876
[TBL] [Abstract] [Full Text] [Related]
11. Hepatic Malignancy in an Infant with Wolf-Hirschhorn Syndrome.
Rutter S; Morotti RA; Peterec S; Gallagher PG
Fetal Pediatr Pathol; 2017 Jun; 36(3):256-262. PubMed ID: 28266898
[TBL] [Abstract] [Full Text] [Related]
12. Two cases of hepatic adenomas in patients with Wolf-Hirschhorn syndrome: a new rare complication?
Prunotto G; Cianci P; Cereda A; Scatigno A; Fossati C; Maitz S; Biondi A; Selicorni A
Am J Med Genet A; 2013 Jul; 161A(7):1759-62. PubMed ID: 23696331
[TBL] [Abstract] [Full Text] [Related]
13. Overexpression of mmset is correlation with poor prognosis in hepatocellular carcinoma.
Zhou P; Wu LL; Wu KM; Jiang W; Li JD; Zhou LD; Li XY; Chang S; Huang Y; Tan H; Zhang GW; He F; Wang ZM
Pathol Oncol Res; 2013 Apr; 19(2):303-9. PubMed ID: 23225158
[TBL] [Abstract] [Full Text] [Related]
